Vertex Pharmaceuticals (VRTX) Share-based Compensation (2009 - 2026)

Vertex Pharmaceuticals' Share-based Compensation history runs 18 years deep, the most recent figure standing at $166.4 million for Q1 2026.

• On a quarterly basis, Share-based Compensation changed 0.18% year-over-year to $166.4 million in Q1 2026; TTM through Mar 2026 was $370.2 million, a 9.66% increase from a year earlier, with the FY2025 full-year figure at $369.9 million, down 8.67% from the prior year.
• Share-based Compensation improved to $166.4 million in Q1 2026 per VRTX's latest filing, from -$158.4 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $233.5 million in Q1 2024 and bottomed at -$158.4 million in Q4 2025.
• The 5-year median for Share-based Compensation is $130.9 million (2023), against an average of $99.7 million.
• Across the five-year window, Share-based Compensation slumped 172.14% in 2022 and surged 9833.33% in 2023, its largest moves.
• Year by year, Share-based Compensation stood at $2.1 million in 2022, then jumped by 9833.33% to $208.6 million in 2023, then slumped by 160.26% to -$125.7 million in 2024, then fell by 26.01% to -$158.4 million in 2025, then soared by 205.05% to $166.4 million in 2026.
• Per Business Quant, the three latest VRTX Share-based Compensation figures stand at $166.4 million (Q1 2026), -$158.4 million (Q4 2025), and $194.9 million (Q3 2025).